What is the 13F Pro Quality Score for PSNL?

13F Pro ranks Personalis, Inc. (PSNL) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View PSNL's current score at https://13fpro.ai/research/PSNL (free sign-up required for the full ranking).

Where does 13F Pro source PSNL data?

All Personalis, Inc. fundamentals and ownership data come directly from SEC EDGAR. Personalis, Inc. files with the SEC under CIK 1527753. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is PSNL in?

Personalis, Inc. (PSNL) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is PSNL research updated on 13F Pro?

PSNL's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Personalis, Inc.(PSNL)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1527753 PSNL stock profile & AI dashboard →

13F Pro Quality Score

15.7/100

Rank #2,744 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

21.4/100

Profitability

6.4/100

Balance Sheet

8.7/100

Earnings Quality

30.0/100

Free Cash Flow

6.2/100

Institutional Flow

73.9/100

Revenue Scale

13.7/100

Dilution Risk

13.5/100

PSNL Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Personalis, Inc. (PSNL), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores PSNL at 15.7/100 on a 32-signal composite quality model, placing it at rank #2,744 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include free cash flow (6.2) and profitability (6.4), which score below median versus the broader universe. Shareholder dilution risk is elevated at 13.5/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Personalis, Inc. reports quarterly revenue of $15.5M, net income of $-30.0M, free cash flow of $-25.7M. Top institutional holders of PSNL by reported 13-F value include Merck & Co.,, Lightspeed Management Company, L.L.C., ARK Investment Management, based on the most recent SEC filings. PSNL trades on the Nasdaq exchange and files with the SEC under CIK 1527753. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PSNL daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Personalis, Inc. directly from SEC EDGAR. Personalis, Inc.'s 13F Pro composite quality score has ranged between 8 and 40 since 2021, currently 15.7 — a declining long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about Personalis, Inc.

Quirks, history, and lore behind PSNL — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. healthcare company · small-cap · listed on Nasdaq · headquartered in California.
2
The Numbers
Annual revenue in the range of tens of millions of dollars, with a heavy focus on R&D spending — profits are not yet the point.
3
The History
Founded in the 2010s, it went public around 2020 and has built its business at the intersection of genomics and clinical medicine.
4
The Secret
Its core platform performs whole-genome sequencing at clinical scale — not just research snippets, but the entire human genome, used to guide cancer care.
5
The Lore
The company has notable partnerships with the U.S. Department of Veterans Affairs and major cancer centers, sequencing patients to match them with the best therapies.
6
The Giveaway
Its name is a riff on 'personal' genomics, its ticker is four letters starting with P, and it promises to make comprehensive genomic profiling routine for every cancer patient.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$15.5M

Net Income

Q1 2026

$-30.0M

Free Cash Flow

Q1 2026

$-25.7M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-5.2% YoY

$69.6MFY 2025

FY21 $85.5MFY22 $65.0MFY23 $73.5MFY25 $69.6M

Net Income

+25.0% YoY

$-81.3MFY 2025

FY21 $-65.2MFY22 $-113.3MFY23 $-108.3MFY25 $-81.3M

Operating Income

+19.9% YoY

$-88.1MFY 2025

FY21 $-65.4MFY22 $-115.5MFY23 $-109.9MFY25 $-88.1M

EPS (Diluted)

+59.6% YoY

$-0.91FY 2025

FY21 $-1.49FY22 $-2.48FY23 $-2.25FY25 $-0.91

Total Assets

+48.5% YoY

$334.2MFY 2025

FY21 $396.5MFY22 $292.7MFY23 $225.1MFY25 $334.2M

Total Debt

—FY 2025

FY21 —FY22 —FY23 —FY25 —

Op. Cash Flow

-33.2% YoY

$-74.9MFY 2025

FY21 $-70.8MFY22 $-70.2MFY23 $-56.3MFY25 $-74.9M

Metric	FY 2025	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Revenue	$69.6M -5.2%	$73.5M +13.0%	$65.0M -23.9%	$85.5M +8.7%	$78.6M +20.6%	$65.2M
Net Income	$-81.3M +25.0%	$-108.3M +4.4%	$-113.3M -73.7%	$-65.2M -58.0%	$-41.3M -64.6%	$-25.1M
Operating Income	$-88.1M +19.9%	$-109.9M +4.8%	$-115.5M -76.8%	$-65.4M -55.1%	$-42.1M -88.0%	$-22.4M
EPS (Diluted)	$-0.91 +59.6%	$-2.25 +9.3%	$-2.48 -66.4%	$-1.49 -24.2%	$-1.20	—
Total Assets	$334.2M +48.5%	$225.1M -23.1%	$292.7M -26.2%	$396.5M +62.0%	$244.8M +55.7%	$157.3M
Total Debt	—	—	—	—	$0.00	$0.00
Operating Cash Flow	$-74.9M -33.2%	$-56.3M +19.9%	$-70.2M +0.8%	$-70.8M -66.1%	$-42.7M -136.1%	$-18.1M

AI Insight: PSNL Financial Trends

Revenue collapsed 35% from Q2 2024 to Q1 2026 while operating losses more than doubled and cash burn accelerated dramatically.

• Revenue declined from $26M in Q3 2024 to $15M in Q1 2026, down 42% over six quarters.

• Operating losses widened from $14M in Q3 2024 to $32M in Q1 2026.

• Operating cash flow deteriorated from $6M outflow in Q3 2024 to $22M outflow in Q1 2026.

⚠ Equity dropped from $261M in Q4 2025 to $255M in Q1 2026 despite no debt burden.

⚠ Revenue volatility remains high with quarterly swings between $14M and $26M over past eight quarters.

AI Insight: PSNL Ratio Trends

Personalis shows severe deterioration with operating margins worsening from -74.8% in Q2 2024 to -160.7% in Q3 2025, while net profit margins plunged to -194.1% in Q1 2026.

• Operating margin deteriorated from -74.8% in Q2 2024 to -160.7% in Q3 2025, showing worsening operational efficiency.

• Net profit margin collapsed to -194.1% in Q1 2026, the worst level in the dataset.

• ROE declined from -30.4% in Q1 2025 to -47.1% in Q1 2026, indicating deepening shareholder value destruction.

• ROIC worsened from -34.1% in Q1 2025 to -50.5% in Q1 2026, reflecting poor capital allocation efficiency.

⚠ All profitability metrics remain deeply negative with no signs of improvement toward breakeven.

⚠ Cash burn rate appears to be accelerating based on worsening margin trends through Q1 2026.

Get alerted when PSNL's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Personalis, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of PSNL

Merck & Co., Inc.
$89.5M14,044,943 sh
Lightspeed Management Company, L.L.C.
$52.0M8,160,734 sh
ARK Investment Management LLC
$50.6M7,944,112 sh
AMERIPRISE FINANCIAL INC
$48.4M7,592,807 sh
BlackRock, Inc.
$34.3M5,389,885 sh
abrdn plc
$22.2M3,488,308 sh
Deep Track Capital, LP
$19.1M3,000,000 sh
AIGH Capital Management LLC
$18.5M2,900,000 sh
VANGUARD CAPITAL MANAGEMENT LLC
$18.3M2,868,463 sh
KENNEDY CAPITAL MANAGEMENT LLC
$13.9M2,183,572 sh

Fund	Value	Shares
Merck & Co., Inc.	$89.5M	14,044,943
Lightspeed Management Company, L.L.C.	$52.0M	8,160,734
ARK Investment Management LLC	$50.6M	7,944,112
AMERIPRISE FINANCIAL INC	$48.4M	7,592,807
BlackRock, Inc.	$34.3M	5,389,885
abrdn plc	$22.2M	3,488,308
Deep Track Capital, LP	$19.1M	3,000,000
AIGH Capital Management LLC	$18.5M	2,900,000
VANGUARD CAPITAL MANAGEMENT LLC	$18.3M	2,868,463
KENNEDY CAPITAL MANAGEMENT LLC	$13.9M	2,183,572

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put PSNL on your watchlist

Track score changes the day Personalis, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is PSNL a good stock to buy?

13F Pro's AI-powered analysis of Personalis, Inc. (PSNL) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for PSNL are available on the PSNL stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own PSNL?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling PSNL. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Personalis, Inc.'s investment landscape.